Compare CMCT & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCT | SNGX |
|---|---|---|
| Founded | 1993 | 1987 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 11.2M |
| IPO Year | 1996 | 2006 |
| Metric | CMCT | SNGX |
|---|---|---|
| Price | $4.69 | $0.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 40.4K | ★ 1.6M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $116,669,000.00 | $119,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.06 | $0.28 |
| 52 Week High | $14.41 | $6.23 |
| Indicator | CMCT | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 50.80 | 34.80 |
| Support Level | $2.59 | $0.28 |
| Resistance Level | $5.08 | $0.41 |
| Average True Range (ATR) | 0.52 | 0.04 |
| MACD | -0.28 | 0.03 |
| Stochastic Oscillator | 7.40 | 91.77 |
Creative Media & Community Trust Corp is a Maryland corporation and REIT. It mainly acquires, develops, owns, and operates both multifamily properties situated in vibrant communities throughout the United States and Class A and creative office real assets in markets with similar business and employment characteristics to multifamily investments. All of its communities are located in areas that include traditional downtowns and suburban main streets, which have high barriers to entry, high population density, positive population trends, and a propensity for growth. Currently, the company consists of three types of commercial real estate properties, namely office, hotel, and multifamily.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).